The Role of PET in Staging Non-Small Cell Lung Cancer.
- Author:
In Young HYUN
1
Author Information
1. Department of Nuclear Medicine, Inha University College of Medicine, Inchon, Korea. iyhyun@dragon.inha.ac.kr
- Publication Type:Review
- Keywords:
F-18 fluorodeoxyglucose (FDG);
non-small cell lung cancer (NSCLC);
positron emission tomography (PET);
staging
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Humans;
Korea;
Lung Neoplasms;
Mediastinoscopy;
Neoplasm Metastasis;
Prognosis
- From:Korean Journal of Nuclear Medicine
2004;38(6):481-485
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Lung cancer has become a leading cause of cancer death in Korea. Accurate staging of non-small cell lung cancer (NSCLC) is essential to the ability to offer a patient the most effective available treatment and the best estimate of prognosis. PET with F-18 fluorodeoxyglucose (FDG) is indicated for the nodal staging of NSCLC and detection of distant metastases. Use of PET for mediastinal staging should not be relied on as a sole staging modality, and positive findings should be confirmed by mediastinoscopy. FDG PET avoids futile surgery by a more accurate selection of patients, especially by the detection of unexpected distant metastases.
